| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| pioglitazone hydrochloride | Tablet, uncoated | 33.06 mg | Anticipated | Available | Manufacturing | 1/09/2024 |
| atropine sulfate monohydrate | Injection, solution | 1.2 mg/mL | Current | Unavailable | Manufacturing | 30/08/2024 |
| gentamicin | Injection, solution | 80 mg | Anticipated | Available | Manufacturing | 30/08/2024 |
| pantoprazole sodium sesquihydrate | Injection, powder for | 45.12 mg | Current | Unavailable | Manufacturing | 30/08/2024 |
| griseofulvin | Tablet | 500 mg | Resolved | Available | Manufacturing | 30/08/2024 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 30/08/2024 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 30/08/2024 |
| adrenaline (epinephrine) | Injection, solution | 1 mg | Current | Limited Availability | Manufacturing | 30/08/2024 |
| Choriogonadotropin alfa | Injection, solution | 250 microgram | Current | Limited Availability | Unexpected increase in consumer demand | 30/08/2024 |
| Alteplase | Injection, powder for | 50 mg | Resolved | Available | Unexpected increase in consumer demand | 30/08/2024 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/08/2024 |
| hydrochlorothiazide~telmisartan | Tablet, film coated | 12.5 mg~80 mg | Current | Limited Availability | Manufacturing | 30/08/2024 |
| temozolomide | Capsule, hard | 100 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 30/08/2024 |
| metformin hydrochloride | Tablet, modified release | 1000 mg | Current | Limited Availability | Manufacturing | 30/08/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 30/08/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Current | Unavailable | Manufacturing | 30/08/2024 |
| epirubicin hydrochloride | Injection, concentrated | 200 mg | Current | Unavailable | Manufacturing | 30/08/2024 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Anticipated | Available | Manufacturing | 30/08/2024 |
| betahistine dihydrochloride | Tablet | 16 mg | Current | Unavailable | Manufacturing | 30/08/2024 |
| bortezomib | Injection, powder for | 2.5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/08/2024 |
| tadalafil | Tablet, film coated | 10 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 30/08/2024 |
| lisdexamfetamine dimesilate | Capsule, hard | 60 mg | Current | Unavailable | Unexpected increase in consumer demand | 30/08/2024 |
| timolol maleate | Eye Drops, solution | 6.83 mg/mL | Anticipated | Available | Commercial Changes / Commercial viability | 30/08/2024 |
| ropinirole hydrochloride | Tablet, film coated | 2.28 mg | Current | Unavailable | Manufacturing | 30/08/2024 |
| tenofovir disoproxil fumarate | Tablet | 300 mg | Current | Limited Availability | Manufacturing | 30/08/2024 |
| celecoxib | Capsule, hard | 100 mg | Anticipated | Available | Manufacturing | 30/08/2024 |
| hydromorphone hydrochloride | Injection, solution | 2 mg | Anticipated | Available | Manufacturing | 30/08/2024 |
| lenalidomide | Capsule, hard | 5 mg | Current | Limited Availability | Unexpected increase in consumer demand | 30/08/2024 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 40 mg~13.88 mg | Current | Unavailable | Manufacturing | 30/08/2024 |
| tirzepatide | Injection, solution | 5 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 30/08/2024 |
| tirzepatide | Injection, solution | 7.5 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 30/08/2024 |
| tirzepatide | Injection, solution | 12.5 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 30/08/2024 |
| tirzepatide | Injection, solution | 10 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 30/08/2024 |
| tirzepatide | Injection, solution | 15 mg | Current | Unavailable | Commercial Changes / Commercial viability | 30/08/2024 |
| tirzepatide | Injection, solution | 2.5 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 30/08/2024 |
| amidotrizoate meglumine~sodium amidotrizoate | Injection, intravenous infusion | 260 mg/mL~40 mg/mL | Current | Unavailable | Manufacturing | 30/08/2024 |
| sodium chloride | Injection, solution | 90 mg | Current | Limited Availability | Manufacturing | 30/08/2024 |
| sodium chloride | Injection, intravenous infusion | 900 mg | Current | Unavailable | Manufacturing | 30/08/2024 |
| timolol maleate | Eye Drops, solution | 6.84 mg/mL | Current | Unavailable | Manufacturing | 30/08/2024 |
| dorzolamide hydrochloride | Eye Drops, solution | 22.26 mg/mL | Anticipated | Available | Manufacturing | 30/08/2024 |
| Alteplase | Diluent, not applicable | 10 mg | Resolved | Available | Unexpected increase in consumer demand | 30/08/2024 |
| timolol maleate~dorzolamide hydrochloride | Eye Drops, solution | 6.83 mg/mL~22.26 mg/mL | Current | Unavailable | Manufacturing | 30/08/2024 |
| rizatriptan benzoate | Wafer | 14.53 mg | Anticipated | Available | Manufacturing | 30/08/2024 |
| prazosin hydrochloride | Tablet, uncoated | 5.5 mg | Current | Unavailable | Manufacturing | 30/08/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Current | Limited Availability | Manufacturing | 30/08/2024 |
| sevelamer hydrochloride | Tablet, film coated | 800 mg | Resolved | Available | Manufacturing | 29/08/2024 |
| bendamustine hydrochloride monohydrate | Injection, powder for | 100 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 29/08/2024 |
| fluticasone propionate | Inhalation, pressurised | 125 microgram/actuation | Anticipated | Available | Unexpected increase in consumer demand | 29/08/2024 |
| phytomenadione | Injection, solution | 10 mg/mL | Resolved | Available | Product recall | 29/08/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 29/08/2024 |
| zopiclone | Tablet, film coated | 7.5 mg | Resolved | Available | Manufacturing | 29/08/2024 |
| escitalopram oxalate | Tablet, film coated | 25.56 mg | Current | Limited Availability | Manufacturing | 28/08/2024 |
| amlodipine besilate | Tablet, uncoated | 6.94 mg | Resolved | Available | Manufacturing | 28/08/2024 |
| trihexyphenidyl (benzhexol) hydrochloride | Tablet, uncoated | 5 mg | Resolved | Available | Manufacturing | 28/08/2024 |
| ondansetron hydrochloride dihydrate | Injection, solution | 10 mg | Resolved | Available | Manufacturing | 28/08/2024 |
| tamsulosin hydrochloride~dutasteride | Capsule, modified release | 400 microgram~500 microgram | Resolved | Available | Manufacturing | 28/08/2024 |
| clonidine hydrochloride | Tablet, uncoated | 100 microgram | Anticipated | Available | Manufacturing | 28/08/2024 |
| levetiracetam | Tablet, film coated | 1000 mg | Current | Unavailable | Manufacturing | 28/08/2024 |
| bicalutamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 28/08/2024 |
| trandolapril | Capsule, hard | .5 mg | Current | Limited Availability | Manufacturing | 28/08/2024 |
| trandolapril | Capsule, hard | 1 mg | Anticipated | Available | Manufacturing | 28/08/2024 |
| trandolapril | Capsule, hard | 2 mg | Current | Limited Availability | Manufacturing | 28/08/2024 |
| trandolapril | Capsule, hard | 4 mg | Current | Limited Availability | Manufacturing | 28/08/2024 |
| Abatacept | Injection | 125.875 mg | Resolved | Available | Unexpected increase in consumer demand | 28/08/2024 |
| timolol maleate~latanoprost | Eye Drops, solution | 6.83 mg/mL~50 microgram/mL | Current | Unavailable | Unexpected increase in consumer demand | 28/08/2024 |
| paclitaxel | Injection, concentrated | 300 mg | Current | Unavailable | Manufacturing | 28/08/2024 |
| conjugated estrogens~bazedoxifene acetate | Tablet, modified release | .45 mg~22.56 mg | Current | Unavailable | Commercial Changes / Commercial viability | 28/08/2024 |
| cinacalcet hydrochloride | Tablet | 33.064 mg | Resolved | Available | Manufacturing | 28/08/2024 |
| cinacalcet hydrochloride | Tablet | 99.191 mg | Current | Unavailable | Manufacturing | 28/08/2024 |
| lacosamide | Tablet, film coated | 150 mg | Anticipated | Available | Manufacturing | 28/08/2024 |
| nebivolol hydrochloride | Tablet | 1.363 mg | Current | Unavailable | Manufacturing | 28/08/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Manufacturing | 28/08/2024 |
| nebivolol hydrochloride | Tablet | 10.9 mg | Current | Limited Availability | Manufacturing | 28/08/2024 |
| mycophenolate mofetil | Tablet, film coated | 500 mg | Resolved | Available | Manufacturing | 28/08/2024 |
| mycophenolate mofetil | Injection, powder for | 500 mg | Current | Unavailable | Manufacturing | 28/08/2024 |
| dasatinib propylene glycol | Tablet, film coated | 116 mg | Current | Limited Availability | Manufacturing | 28/08/2024 |
| sitagliptin fumarate | Tablet, film coated | 128.497 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 28/08/2024 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 28/08/2024 |
| octreotide | Injection, solution | 100 microgram/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 28/08/2024 |
| cisplatin | Injection, solution | 1 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 28/08/2024 |
| vincristine sulfate | Injection, solution | 1 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 28/08/2024 |
| indapamide hemihydrate | Tablet | 2.5 mg | Anticipated | Available | Manufacturing | 28/08/2024 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 27/08/2024 |
| lidocaine hydrochloride monohydrate~adrenaline (epinephrine) acid tartrate | Injection, solution | 21.3 mg/mL~22.7 microgram/mL | Resolved | Available | Manufacturing | 27/08/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| salbutamol sulfate | Inhalation | 1.2 mg/mL | Anticipated | Available | Manufacturing | 27/08/2024 |
| risperidone | Tablet | .5 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| risperidone | Tablet | 1 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| ondansetron hydrochloride dihydrate | Injection, solution | 5 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| dopamine hydrochloride | Injection, concentrated | 40 mg/mL | Anticipated | Available | Manufacturing | 27/08/2024 |
| levetiracetam | Tablet, film coated | 250 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 27/08/2024 |
| bisoprolol fumarate | Tablet | 2.5 mg | Current | Limited Availability | Manufacturing | 27/08/2024 |
| ropivacaine hydrochloride | Injection, solution | 400 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 27/08/2024 |
| zolmitriptan | Tablet, film coated | 2.5 mg | Anticipated | Available | Manufacturing | 27/08/2024 |
| quetiapine fumarate | Tablet, film coated | 115.12 mg | Anticipated | Available | Manufacturing | 27/08/2024 |
| simvastatin | Tablet, film coated | 20 mg | Resolved | Available | Manufacturing | 27/08/2024 |
| pemetrexed disodium | Injection, powder for | 110.28 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| pemetrexed disodium | Injection, powder for | 551.4 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| pemetrexed disodium | Injection, powder for | 1102.8 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| rosuvastatin calcium | Tablet, film coated | 41.68 mg | Resolved | Available | Commercial Changes / Commercial viability | 27/08/2024 |
| voriconazole | Injection, powder for | 200 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| emtricitabine~tenofovir disoproxil fumarate | Tablet, film coated | 200 mg~300 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 27/08/2024 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 27/08/2024 |
| risperidone | Oral Liquid, solution | 1 mg/mL | Current | Unavailable | Manufacturing | 27/08/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Manufacturing | 27/08/2024 |
| nebivolol hydrochloride | Tablet | 10.9 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Resolved | Available | Unexpected increase in consumer demand | 27/08/2024 |
| mycophenolate sodium | Tablet, enteric coated | 384.7 mg | Anticipated | Available | Manufacturing | 27/08/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| carmustine | Injection, powder for | 100 mg | Current | Limited Availability | Manufacturing | 27/08/2024 |
| cefaclor monohydrate | Oral Liquid, powder for | 26.22 mg/mL | Resolved | Available | Manufacturing | 27/08/2024 |
| sodium valproate | Tablet, enteric coated | 500 mg | Resolved | Available | Manufacturing | 27/08/2024 |
| clonazepam | Tablet, uncoated | 2 mg | Current | Limited Availability | Manufacturing | 27/08/2024 |
| captopril | Tablet, uncoated | 50 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| flecainide acetate | Tablet, uncoated | 100 mg | Resolved | Available | Manufacturing | 27/08/2024 |
| enalapril maleate | Tablet, uncoated | 5 mg | Resolved | Available | Manufacturing | 27/08/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Anticipated | Available | Manufacturing | 27/08/2024 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Resolved | Available | Manufacturing | 27/08/2024 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Resolved | Available | Manufacturing | 27/08/2024 |
| baclofen | Tablet, uncoated | 25 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 27/08/2024 |
| famotidine | Tablet, film coated | 20 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| famotidine | Tablet, film coated | 40 mg | Current | Unavailable | Manufacturing | 27/08/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 36 mg | Resolved | Available | Manufacturing | 27/08/2024 |
| metformin hydrochloride | Tablet, modified release | 500 mg | Discontinued | Unavailable | Manufacturing | 26/08/2024 |
| perindopril erbumine | Tablet, uncoated | 2 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/08/2024 |
| perindopril erbumine | Tablet, uncoated | 4 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 26/08/2024 |
| perindopril erbumine | Tablet, uncoated | 8 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/08/2024 |
| Epoetin lambda | Injection, solution | 10000 IU | Current | Limited Availability | Manufacturing | 26/08/2024 |
| gabapentin | Tablet, film coated | 600 mg | Anticipated | Available | Manufacturing | 26/08/2024 |
| insulin~insulin | Injection, suspension | 30 IU/mL~70 IU/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 26/08/2024 |
| perindopril erbumine | Tablet | 8 mg | Resolved | Available | Manufacturing | 26/08/2024 |
| bisoprolol fumarate | Tablet | 5 mg | Anticipated | Available | Manufacturing | 26/08/2024 |
| bisoprolol fumarate | Tablet | 10 mg | Anticipated | Available | Manufacturing | 26/08/2024 |
| bosentan monohydrate | Tablet, film coated | 64.541 mg | Current | Unavailable | Manufacturing | 26/08/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 26/08/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 26/08/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 26/08/2024 |
| dasatinib | Tablet, film coated | 70 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 26/08/2024 |
| atomoxetine hydrochloride | Capsule, hard | 45.5 mg | Current | Unavailable | Manufacturing | 26/08/2024 |
| escitalopram oxalate | Tablet, film coated | 25.47 mg | Current | Unavailable | Manufacturing | 26/08/2024 |
| bupivacaine hydrochloride monohydrate~adrenaline (epinephrine) acid tartrate | Injection, solution | 5.27 mg/mL~9.1 microgram/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 26/08/2024 |
| estradiol | Drug delivery system, transdermal | 1.56 mg | Current | Limited Availability | Manufacturing | 26/08/2024 |
2024年9月2日